Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
West Palm Beach, FL, March 19, 2018 -- For the first time, a groundbreaking new study is going to be conducted at a national treatment center. Ambrosia Treatment Center announced this month that they have been selected by Nova Southeastern University to participate in a cutting-edge drug study about the long-term effects of Gabapentin. Gabapentin, a drug for nerve pain, is administered by treatment centers across the nation to help clients suffering from the uncomfortable side effects of alcohol and cocaine withdrawal. If taken incorrectly, Gabapentin can be abused and hinder the recovery process. The study will be the first of its kind to see if the drug itself can be addictive.
|
|||
“Gabapentin is a controlled substance, and we need to learn more about this drug so it can continue to be used positively and correctly for the future of our client’s long-term success,” says Ambrosia Treatment Center founder Jerry Haffey Sr. “We have never opened our doors to a study of this magnitude, but we believe the findings will help us and treatment centers across the country better understand this drug and continue to help clients recover from addiction properly.”
Nova Southeastern University will select 100 clients from Ambrosia Treatment Center throughout the course of the year-long study to gain more insight on the effects of Gabapentin. Ambrosia Treatment Center has three locations in Palm Beach County, one in Beverly Hills and another in New Jersey. The study will be conducted at one of its three Palm Beach County locations.
About Ambrosia
Ambrosia Treatment Center has been raising industry standards for over 10 years and has treated over 10,000 clients at our locations nationwide. Our focus is on quality care, family involvement and advancing addiction medicine. To learn more, visit AmbrosiaTC.com.
Attachment:
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/69f87b5a-6917-450a-8df2-a49150f55533
Parker Horveath Ambrosia Treatment Center 5615788600 [email protected]
